Neoplasms

Heart and Blood Diseases

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Neoplasms by Histologic Type

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

Treatment consisted of 8 weekly infusions of 2.4 mg/kg of XL999 with each infusion given over 4 hours, unless drug-related toxicity required a dosing delay or adjustment. In the absence of progressive disease and unacceptable toxicity, subjects may have received XL999 treatment weekly for up to 1 year on this study.

XL999

Lynne Bui, MD

This clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of XL999 when given weekly to patients with relapsed or refractory multiple myeloma. XL999 is a small molecule inhibitor of cellular factors including VEGFR, PDGFR, and FGFR that may be involved in multiple myeloma.

Study of XL999 in Patients With Multiple Myeloma

A Phase 2 Study of XL999 in Subjects With Relapsed/Refractory Multiple Myeloma

Symphony Evolution, Inc.

Charles W. Finn, PhD, President and CEO

Digestive System Diseases

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Herbal and Botanical

All Drugs and Chemicals

Cola

XL999 will be administered at 2.4 mg/kg as a 4-hour intravenous (IV) infusion. Subjects will receive XL999 infusions weekly for 8 weeks of treatment unless drug-related toxicity requires dosing delay. In the absence of progressive disease and unacceptable toxicity, subjects may receive XL999 treatment weekly for up to a year on this study. After 8 weeks, at the discretion of the investigator, one dose of four may be omitted for a subject's convenience.

This clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of XL999 when given weekly to patients with metastatic colorectal cancer (CRC). XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blood vessels (angiogenesis), and metastasis.

Study of XL999 in Patients With Metastatic Colorectal Cancer

A Phase 2 Study of XL999 Administered Intravenously to Subjects With Metastatic Colorectal Cancer

Respiratory Tract (Lung and Bronchial) Diseases

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

• The Study Treatment Period, in which subjects received a once-weekly, 4-hour intravenous (IV) infusion of XL999 at 2.4 mg/kg as outpatients for 8 weeks. Treatment was to be stopped at the occurrence of disease progression or unacceptable toxicity.

Paul Woodard, MD

This clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of XL999 when given weekly to patients with non-small cell lung cancer (NSCLC). XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blood vessels (angiogenesis), and metastasis.

Study of XL999 in Patients With Non-small Cell Lung Cancer

A Phase 2 Study of XL999 Administered Intravenously to Subjects With Non-Small-Cell Lung Cancer

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Symptoms and General Pathology

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Hypersensitivity

Recurrence

Endocrine Gland Neoplasms

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Endocrine System Diseases

Gonadal Disorders

Neoplasms, Glandular and Epithelial

Ovarian Cancer

Ovarian Epithelial Cancer

Treatment was administered on an outpatient basis. XL999 was administered at 2.4 mg/kg as a 4 hour intravenous (IV) infusion. Subjects received a XL999 infusion once a week for 8 weeks of treatment unless drug-related toxicity required a dosing delay

Lynne A. Bui, MD

This clinical trial is being conducted at multiple sites to evaluate the activity, safety, and tolerability of XL999 when given weekly to patients with ovarian cancer that has previously been treated with platinum-based chemotherapy. XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blood vessels (angiogenesis), and metastasis.

Study of XL999 in Patients With Previously Treated Ovarian Cancer

A Phase 2 Study of XL999 Administered Intravenously to Subjects With Recurrent Ovarian Cancer

Leukemia

Leukemia, Myeloid

Leukemia, Myeloid, Acute

Myeloid Leukemia

Acute Myeloid Leukemia

Acute Non Lymphoblastic Leukemia

Acute Graft Versus Host Disease

XL999 was administered at a dose of 2.4 mg/kg given as a 4-hour IV infusion weekly for 4 weeks. In the absence of progressive disease and unacceptable toxicity, subjects were to receive XL999 treatment weekly for up to 1 year on this study

This clinical study is being conducted at multiple sites to determine the activity, safety and tolerability of XL999 when given weekly to patients with relapsed or newly-diagnosed AML. XL999 is a small molecule inhibitor against Flk1/kinase insert domain receptor (KDR), PDGFR, c-Kit, FLT3 and SRC. c-Kit and FLT3 are receptors commonly expressed on AML blasts.

Study of XL999 in Patients With Acute Myeloid Leukemia (AML)

A Phase 2 Study of XL999 Administered Intravenously to Subjects With Acute Myeloid Leukemia

XL999 will be administered as a once-weekly 4 hour IV infusion as a single agent. The first cohort will be dosed at 0.4 mg/kg IV once weekly. The maximum dose cohort will not exceed 1.6 mg/kg IV once weekly. Ten subjects are planned for each dosing cohort, with dose escalation dependent on safety and available PK data from prior cohorts

The purpose of this study is to determine the safest dose of XL999 and how well subjects with Non-Small-Cell Lung Cancer tolerate XL999. XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blood vessels (angiogenesis), and metastasis.

Safety Study of XL999 in Adults With Non-Small-Cell Lung Cancer

A Phase 1 Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL999 Administered Intravenously to Subjects With Non-Small-Cell Lung Cancer (NSCLC)

Pharmaceutical Solutions

XL999 for injection will be supplied as a brown, sterile injectable solution at a concentration of 5 mg/mL

Charles W. Finn, PhD

The primary objective of this study is to allow rollover of the two remaining subjects from the other XL999 studies to continue to receive XL999.

The secondary objectives of this study are as follows:

* To evaluate tumor response after long term repeat administration of XL999 in two subjects rolled over from other XL999 studies.
* To characterize the long term safety and tolerability of XL999 after repeat administration in two subjects rolled over from other XL999 studies.
* To characterize the long term effects of XL999 on cardiac function after repeat administration in two subjects rolled over from other XL999 studies.

Maintenance Study on the Long Term Safety of XL999

A Maintenance Study Evaluating the Long Term Safety of XL999 Administered Intravenously to Subjects With Advanced Malignancies Previously Enrolled in Other XL999 Studies

Charles W Finn

XL999 was to be given biweekly to an initial cohort of subjects at 0.20 mg/kg and to successive cohorts at doses that escalated by cohort according to a design for safely determining an MTD. After determination of the MTD, one or more additional cohorts were to receive XL999 weekly at the MTD or a lower dose, as determined by the CRC on the basis of interim safety and PK data. By a protocol amendment after initiation of the study, subjects were to be enrolled in an additional cohort to receive a weekly XL999 dose of 200 mg.

The purpose of this study is to assess the safety and tolerability of XL999 in adults with advanced solid tumors.

Study of XL999 in Adults With Solid Tumors

A Phase 1 Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL999 Administered Intravenously to Subjects With Solid Tumors

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Study of XL999 in Patients With Multiple Myeloma	NCT00304590	Multiple Myelom...	XL999	18 Years -	Symphony Evolution, Inc.
Study of XL999 in Patients With Metastatic Colorectal Cancer	NCT00277303	Colorectal Canc...	XL999	18 Years -	Symphony Evolution, Inc.
Study of XL999 in Patients With Non-small Cell Lung Cancer	NCT00277329	Non-small Cell ...	XL999	18 Years -	Symphony Evolution, Inc.
Study of XL999 in Patients With Previously Treated Ovarian Cancer	NCT00277290	Ovarian Cancer	XL999	18 Years -	Symphony Evolution, Inc.
Study of XL999 in Patients With Non-small Cell Lung Cancer	NCT00277329	Non-small Cell ...	XL999	18 Years -	Symphony Evolution, Inc.
Study of XL999 in Patients With Acute Myeloid Leukemia (AML)	NCT00322673	Acute Myeloid L... AML	XL999	18 Years -	Symphony Evolution, Inc.
Safety Study of XL999 in Adults With Non-Small-Cell Lung Cancer	NCT00491699	Non-Small-Cell ...	XL999	18 Years -	Symphony Evolution, Inc.
Maintenance Study on the Long Term Safety of XL999	NCT00955084	Advanced Malign...	XL999	18 Years -	Symphony Evolution, Inc.
Study of XL999 in Patients With Multiple Myeloma	NCT00304590	Multiple Myelom...	XL999	18 Years -	Symphony Evolution, Inc.
Study of XL999 in Patients With Metastatic Colorectal Cancer	NCT00277303	Colorectal Canc...	XL999	18 Years -	Symphony Evolution, Inc.
Study of XL999 in Patients With Non-small Cell Lung Cancer	NCT00277329	Non-small Cell ...	XL999	18 Years -	Symphony Evolution, Inc.
Study of XL999 in Adults With Solid Tumors	NCT00104117	Cancer	XL999	18 Years -	Symphony Evolution, Inc.

Spots Global Cancer Trial Database for xl999

Every month we try and update this database with for xl999 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for xl999

Every month we try and update this database with for xl999 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for xl999 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.